Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6

S. J. DeNardo, L. F. O'Grady, Carol M Richman, Gerald L Denardo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

131I chimeric L6 (ChL6) monoclonal antibody (MoAb) therapy has been performed in 12 patients with advanced, metastatic breast cancer. The protocol was designed to determine the maximum tolerated dose (MTD) of radioimmunotherapy that could be administered at 4 intervals. Ten patients received 20-70 mCi/m2 of 131I ChL6. Two of the patients received granulocyte colony stimulating factor (GCSF) on days 10-20 post therapy. The MTD for two doses was 60 mCi/m2 and thrombocytopenia was the dose limiting toxicity in the absence of marrow reconstitution with stem cells. Two patients received 150 mCi/m2 with autologous peripheral blood stem cell support 7 and 9 days post treatment. The MTD has not been reached for 131I-ChL6 with autologous stem cell support. In the 12 patients treated with 131I ChL6, six patients (50%) had measurable tumor regressions greater than 30% of the sum of the largest two dimensional products for measurable tumors. Four of these 6 patients had a partial response (PR), i.e., ≥ 50% reduction in tumor size. These therapeutic responses associated with modest clinical toxicity in heavily pretreated patients suggest that clinically relevant radioimmunotherapeutic approaches can be devised for metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)203-211
Number of pages9
JournalAdvances in Experimental Medicine and Biology
Volume353
StatePublished - 1994

Fingerprint

Radioimmunotherapy
Stem cells
Tumors
Breast Neoplasms
Toxicity
Maximum Tolerated Dose
Granulocyte Colony-Stimulating Factor
Blood
Monoclonal Antibodies
Stem Cells
Neoplasms
Therapeutics
Thrombocytopenia
Bone Marrow

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. / DeNardo, S. J.; O'Grady, L. F.; Richman, Carol M; Denardo, Gerald L.

In: Advances in Experimental Medicine and Biology, Vol. 353, 1994, p. 203-211.

Research output: Contribution to journalArticle

@article{2576e27f31464307bdbb82f803674d10,
title = "Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6",
abstract = "131I chimeric L6 (ChL6) monoclonal antibody (MoAb) therapy has been performed in 12 patients with advanced, metastatic breast cancer. The protocol was designed to determine the maximum tolerated dose (MTD) of radioimmunotherapy that could be administered at 4 intervals. Ten patients received 20-70 mCi/m2 of 131I ChL6. Two of the patients received granulocyte colony stimulating factor (GCSF) on days 10-20 post therapy. The MTD for two doses was 60 mCi/m2 and thrombocytopenia was the dose limiting toxicity in the absence of marrow reconstitution with stem cells. Two patients received 150 mCi/m2 with autologous peripheral blood stem cell support 7 and 9 days post treatment. The MTD has not been reached for 131I-ChL6 with autologous stem cell support. In the 12 patients treated with 131I ChL6, six patients (50{\%}) had measurable tumor regressions greater than 30{\%} of the sum of the largest two dimensional products for measurable tumors. Four of these 6 patients had a partial response (PR), i.e., ≥ 50{\%} reduction in tumor size. These therapeutic responses associated with modest clinical toxicity in heavily pretreated patients suggest that clinically relevant radioimmunotherapeutic approaches can be devised for metastatic breast cancer.",
author = "DeNardo, {S. J.} and O'Grady, {L. F.} and Richman, {Carol M} and Denardo, {Gerald L}",
year = "1994",
language = "English (US)",
volume = "353",
pages = "203--211",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6

AU - DeNardo, S. J.

AU - O'Grady, L. F.

AU - Richman, Carol M

AU - Denardo, Gerald L

PY - 1994

Y1 - 1994

N2 - 131I chimeric L6 (ChL6) monoclonal antibody (MoAb) therapy has been performed in 12 patients with advanced, metastatic breast cancer. The protocol was designed to determine the maximum tolerated dose (MTD) of radioimmunotherapy that could be administered at 4 intervals. Ten patients received 20-70 mCi/m2 of 131I ChL6. Two of the patients received granulocyte colony stimulating factor (GCSF) on days 10-20 post therapy. The MTD for two doses was 60 mCi/m2 and thrombocytopenia was the dose limiting toxicity in the absence of marrow reconstitution with stem cells. Two patients received 150 mCi/m2 with autologous peripheral blood stem cell support 7 and 9 days post treatment. The MTD has not been reached for 131I-ChL6 with autologous stem cell support. In the 12 patients treated with 131I ChL6, six patients (50%) had measurable tumor regressions greater than 30% of the sum of the largest two dimensional products for measurable tumors. Four of these 6 patients had a partial response (PR), i.e., ≥ 50% reduction in tumor size. These therapeutic responses associated with modest clinical toxicity in heavily pretreated patients suggest that clinically relevant radioimmunotherapeutic approaches can be devised for metastatic breast cancer.

AB - 131I chimeric L6 (ChL6) monoclonal antibody (MoAb) therapy has been performed in 12 patients with advanced, metastatic breast cancer. The protocol was designed to determine the maximum tolerated dose (MTD) of radioimmunotherapy that could be administered at 4 intervals. Ten patients received 20-70 mCi/m2 of 131I ChL6. Two of the patients received granulocyte colony stimulating factor (GCSF) on days 10-20 post therapy. The MTD for two doses was 60 mCi/m2 and thrombocytopenia was the dose limiting toxicity in the absence of marrow reconstitution with stem cells. Two patients received 150 mCi/m2 with autologous peripheral blood stem cell support 7 and 9 days post treatment. The MTD has not been reached for 131I-ChL6 with autologous stem cell support. In the 12 patients treated with 131I ChL6, six patients (50%) had measurable tumor regressions greater than 30% of the sum of the largest two dimensional products for measurable tumors. Four of these 6 patients had a partial response (PR), i.e., ≥ 50% reduction in tumor size. These therapeutic responses associated with modest clinical toxicity in heavily pretreated patients suggest that clinically relevant radioimmunotherapeutic approaches can be devised for metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0027936896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027936896&partnerID=8YFLogxK

M3 - Article

C2 - 7527179

AN - SCOPUS:0027936896

VL - 353

SP - 203

EP - 211

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -